Wednesday, July 8, 2026

pharma · Epidermolysis Bullosa Simplex · INM

InMed Pharmaceuticals

InMed Pharmaceuticals patent portfolio — 15 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Vancouver, CA HQ
19 Employees
Public company Type
INM · NYSE Ticker
Company details
Status
Public
HQ
Vancouver, CA
Employees
19
Programs
1
Drugs
0
Patents
15
Intelligence · Patents

InMed Pharmaceuticals patents

15 pharmaceutical patents indexed for InMed Pharmaceuticals. 3 expire within 24 months.

InMed Pharmaceuticals has 15 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 3 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12357604

    Topical formulations of cannabinoids and use thereof in the treatment of pain

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12083229

    Ocular drug delivery formulation

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12042479

    Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11472840

    Acetylcholine receptor-binding peptide

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11471534

    Chitosan-pluronic complex and nano-carrier comprising same

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 8361485

    Conditioned cell culture medium compositions and methods of use

    Expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 8268336

    Compositions containing aromatic aldehydes and their use in treatments

    Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 8246969

    Compositions containing aromatic aldehydes and their use in treatments

    Expires Mon Aug 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 8246971

    Compositions containing aromatic aldehydes and their use in treatment

    Expires Mon Aug 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 8236288

    Melanin modification compositions and methods of use

    Expires Mon Aug 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 8138147

    Conditioned cell culture medium compositions and methods of use

    Expires Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 7374770

    Topical composition for follicular delivery of an ornithine decarboxylase inhibitor

    Expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 7160726

    Compositions comprising conditioned cell culture media and uses thereof

    Expires Mon Jan 04 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 7118746

    Conditioned cell culture medium compositions and methods of use

    Expires Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 6896909

    Formulations containing iron ores for the topical treatment of bioenergetic and electromagnetic disorders

    Expires Mon May 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does InMed Pharmaceuticals have?

15 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do InMed Pharmaceuticals patents expire?

3 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.